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Abstract
Foot problems are commonly involved in diabetes, and the most common 
presentation of diabetes is an ulcer. Diabetic foot ulcer is a complex problem caused 
by reduced blood supply, nerve damage, or infection. But unfortunately in most 
of cases, these three factors have played a role for impairment of diabetic feet. 
Sometimes nerve damage or neuropathy is an initial insult, and multiple times 
ischemia is the leading factor for ulcer formation. After certain period, infection 
finally supervenes and makes a sterile ulcer to infected leads to loss of limb or foot. 
This becomes more complicated because of less pronounced ischemic symptoms in 
diabetic than non-diabetics. Furthermore, the healing of a neuroischemic ulcer is 
slowed down by microvascular dysfunction. Therefore, some ulcers can get better 
by revascularization, but pure ischemic ulcers rarely respond to revascularization. 
Many guidelines have largely ignored these specific demands related to ulcerated 
neuroischemic diabetic feet. Any diabetic foot ulcer should always be considered to 
have vascular impairment unless otherwise proven. This chapter highlights the best 
way to diagnose and treat these patients with diabetic foot ulcer. Most of the studies 
dealing with neuroischemic diabetic feet are not comparable in terms of patient 
populations, interventions, or outcomes. Therefore, there is an urgent need for a 
paradigm shift in diabetic foot care, that is, a new approach and classification of 
diabetics with foot ulcer in regard to clinical practice and research.
Keywords: diabetic, ulcer, Hyderabad, diabetic foot, diabetic foot ulcer, 
revascularization
1. Introduction
Diabetic foot ulcer is a late and disfiguring complication, which leads to higher 
risk of amputation of any part of the foot or leg. Therefore diabetic foot disease has 
major medical, economic, and social consequences. It is very important to treat it 
with proper protocol to save patients from fatal and disabling complications.
The complexity is to understand the main insult which can be diabetic periph-
eral arterial disease, neuropathy, or infection. The healing process is also halted due 
to impaired collagen synthesis. Vascular disease varies from arteritis, occlusion, and 
large vessel atherosclerosis.
The diabetic foot ulcer is a cave of infection, severe vessel ischemia, and multiple 
painless traumas. Factors that exacerbate the problem are advanced age, duration of 
the diabetes, and control of diabetes.
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Diabetic foot ulcers are classified in many ways, but many systems of classifica-
tion are complex to interpret. Hence, particular attention to feet care should be a 
central focus in educating and managing patients with diabetes to ensure that ulcer 
is either prevented or noticed early enough.
2. Classification and epidemiology of diabetes and foot ulcer
Persistent elevation of blood sugar is associated with major metabolic abnor-
malities in diabetic patients and damages to various organs and systems, leading to 
life-threatening complications, which can be overt like major cardiovascular events 
and cerebrovascular accidents or covert such as retinopathy or nephropathy.
Diabetes mellitus is broadly classified into four types by etiology and clini-
cal presentation, type 1 diabetes, type 2 diabetes, gestational diabetes (GDM), 
and other less common types of diabetes, which include monogenic diabetes and 
secondary diabetes.
1. Type 1 diabetes, which involves autoimmune beta-cell destruction, leads to 
absolute insulin deficiency.
In the past decade, there was a 21% increase in the number of type 1 diabetes in 
the USA [1], and the prevalence is increasing at a rate of 3% per year globally 
[2]. Another study reported that the annual increase was 2% in type 1 diabetes 
and 5% for type 2 diabetes [3].
There is no gender variation in type 1 diabetes [4], and type 1 diabetes reduce 
life expectancy by 13 years as per data reported [5]. Approximately 15% of 
adults to diagnosed with type 2 diabetes have actually latent autoimmune dia-
betes of adults, which are a variant of type 1 diabetes [6].
2. Type 2 diabetes (steady loss of beta-cell insulin secretion or insulin resistance).
3. Gestational diabetes mellitus (GDM) (diabetes diagnosed in the second or 
third trimester of pregnancy).
4. Specific types of diabetes due to other causes:
• maturity-onset diabetes of the young [MODY] or neonatal diabetes;
• diseases of the pancreas, for example, cystic fibrosis and chronic  
pancreatitis; and
• drug- or chemical-induced diabetes.
Nearly 463 million adults (20–79 years of age) are living with diabetes; by 2045, 
this will rise to 700 million. The proportion of people with type 2 diabetes is 
increasing in most countries, and 79% of adults with diabetes are living in low- 
and middle-income countries. The greatest number of people with diabetes is 
between 40 and 59 years of age.
In past year, subcontinents were affected enormously. It was estimated that 
nearly 20 million adults in Pakistan were diabetics, putting them at risk for major or 
minor complications, and approximately 8 million are still undiagnosed [7].
There are many contributing risk factors for type 2 diabetes: poor socioeco-
nomic status, reduced literacy in 41%, low occupation in 31%, and less income in 
40% [8].
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More than 15% of diabetic people during their lives experience foot ulcers [6]. 
These ulcers account for more than 80% of nontraumatic lower limb amputations 
[9]. The burden of foot ulcer in diabetes varies from 3% in Oceania to 13% in 
North America, Canada (14.8%), Asia 5.5%, and Europe 5.1% [10].
The annual incidence of diabetic foot ulcer or necrosis in diabetic patients is 
known to be about 2–5%, and the lifetime risk ranges from 15 to 20% [11].
3. Risk factors for diabetic foot ulcer
Males are affected more than females, and it is more common in the elderly 
above 60 years of age. Several studies have reported racial predisposition. One 
author has evaluated that the increased risk of amputation in African blacks was 
2- to 3-fold higher than that in whites [12].
The diabetic foot ulcer is seen in lower socioeconomic class (78.2%) [13]. 
Smoking aggravates macrovascular complications including peripheral  
arterial disease.
It has been observed that 47% of patients who had previous ulceration walked 
barefooted within the house and 17% walked barefooted outside [14]. Neuropathy 
was involved in more than half of diabetic foot ulcers [15], while peripheral vascu-
lar disease accounts for about 15% alone and 35% in conjunction with neuropathy. 
The unequilibrated distribution of pressure in the foot during walking exposes 
pressure bearing points to ulceration [16]. The previous foot ulcers have tendency 
to develop recurrent diabetic foot ulcers.
Previous amputation is undoubtedly a big risk factor in 50% of the diabetic 
foot ulcers. Inappropriate footwears produce foot ulcer frequently in diabetes. 
Poor vision contributes due to diabetic retinopathy with the patient unable to prop-
erly identify injurious objects. Minor or major trauma to foot could be an origin of 
a chronic ulcer or wound.
4. Pathogenesis of diabetic foot ulcer
It is a worst combination of neuropathy and ischemia. It becomes more com-
plicated by infection. This process leads to impaired wound healing, decreased cell 
growth factor response, reduced tissue perfusion, and decreased local angiogenesis.
The precise pattern of diabetic neuropathy is not yet completely understood. 
More evidence has identified the polyol pathway as a major factor in diabetic neu-
ropathy, which leads to oxidative injury. It becomes more complicated when com-
bined with osmotic cell-induced nerve damage, which triggers nerve cell edema. 
More than half of foot ulcers were caused by neuropathy [17].
Multiple neuropathies are involved in diabetic foot ulcer, which cause impaired 
pain sensation and impaired temperature sensation. Sensory diabetic neuropathy 
increases incidence of ulcer at foot approximately sevenfold, compared to diabetic 
patients without sensory neuropathy [18].
Finally ulcer appeared which may become chronic and combined to atrophy 
of foot muscles, flexion extension imbalance and also impaired equilibrium. 
Progressively, repeated pressure at focal points within the foot leads to ulceration. 
Furthermore, there is reduced sweating and dryness of the skin predisposing 
to cracks, which become potential sites for frequent ulceration and portals for 
 bacterial entry.
Peripheral arterial disease is a macrovascular complication and an essential 
contributor to diabetic foot. The endothelial dysregulation that occurs in diabetes 
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leads to reduced production of nitrous oxide (NO), which is a dependable vasodila-
tor and regulates smooth muscle proliferation and leucocyte adhesion, resulting in 
atherosclerosis and vascular narrowing and ischemia.
The limb or foot ischemia can happen even in the presence of palpable pedal 
pulses [19].
Also, hyperglycemia promotes increased levels of fibrinogen and plasminogen 
activator inhibitor which impairs fibrinolysis [20]. These and other abnormalities 
promote platelet adhesion and thrombosis. In addition, the formation of advanced 
glycation end products which are compounds formed by the nonenzymatic 
reaction between sugars and proteins leads to cross linking of molecules in the 
extracellular matrix of the basement membrane. This alters the structure of the 
vessels and promotes stiffness [21]. There is also an increased expression of growth 
factors and adhesion molecules, e.g., intracellular adhesion molecule 1 and vascu-
lar endothelial growth factor [22]. Dyslipidemia also contributes to atherosclerosis. 
In fact, a 1% increase in HbA1C is related to 25–28% of relative risk of peripheral 
arterial disease [23–26].
Wound healing is defective in diabetes partly due to deficient angiogenesis. 
It has been noticed that abnormal excessive and inadequate angiogenesis occurs 
with diabetic complications, delayed closure time, and impaired tissue remodeling 
[27]. The inadequate mobilization of bone marrow-derived endothelial progenitor 
cells (EPCs) to the site of injury is another possible mechanism of impaired heal-
ing. These cells respond to ischemia and populate the injury site where they form 
new vessels [28].
About 60% of diabetic foot ulcers have been infected which could be superficial, 
deep, or more complex such as osteomyelitis [29]. Although typical signs and symp-
toms could be absent, severe infection could present with systemic symptoms, e.g., 
fever, chills, and tachycardia. The Infectious Diseases Society of America (IDSA) 
criteria for severe diabetic foot infection are temperature of >100°F, tachycardia, 
tachypnea or respiratory alkalosis, leukocytosis, or leucopenia [30]. The commonly 
isolated organisms are Staphylococcus aureus, S. epidermidis, and Streptococcus spe-
cies. Methicillin-resistant S. aureus (MRSA) complicates 32% of infections, and it is 
associated with treatment failure. Among anaerobes, Peptostreptococcus magnus and 
Bacteroides fragilis have been isolated. The majority of cases are polymicrobial. S. 
aureus, Group B Streptococcus, and gram-negative Bacilli are associated with limb-
threatening infections [31].
5. Classification of diabetic foot ulcer
Wagner classification system: This system focused on physical characteristics 
of ulcer, depth, and the presence of osteomyelitis or gangrene (0–5) [32].
SINBAD ƒ assesses site, ischemia, neuropathy, bacterial infection, and depth 
and uses a scoring system 0–6. It has been focused on clinical and gross pathological 
changes of ulcer.
PEDIS classification: This system was designed by the International Working 
Group on the Diabetic Foot and uses the same five components of S(AD) SAD: perfu-
sion, extent, depth, infection, and sensation. It does not include ulcer location [33].
DEPA classification: This system looks at four aspects of ulcers: depth, extent 
of bacterial colonization, phase of healing, and associated etiology. Each category is 
scored from 1 to 3 according to severity.
University of Texas ƒ has been proven effective at predicting lower extremity 
amputation when combined with Wagner classification, and it comprises four 
grades, A to D, and four stages, 1–4 [34].
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Kobe’s Classification focused on neuropathy, infection and vasculopathy: Type 1, 
mainly peripheral neuropathy (PN); type 2, mainly peripheral arterial disease (PAD); 
type 3, mainly infection; and type 4: all three combined, neuropathy, peripheral arte-
rial disease with infection [35].
SAD stands for sepsis, arteriopathy, and denervation system. The major draw-
back of this classification is that it is potentially complex and is primarily intended 
for selecting population for prospective research [36].
Diabetic Ulcer Severity Score (DUSS)
The Diabetic Ulcer Severity Score (DUSS) is based on the categorization of 
wounds into specific severity subgroups for a comparison of outcomes. Assessment 
using the DUSS system includes the presence of pedal pulses, the ability to probe 
to the bone within the ulcer, and ulcer quantity and location. The sum of points 
determines severity, with the score ranging from 0 to 4.
6. Approach to diabetic foot ulcer
7. Assessment of risk
8. Investigations
• CBC
• Renal function tests
• CRP and ESR
Feature Neuropathic Ischemic Neuroischemic
Sensation Sensory loss Pain Degree of sensory loss
Callus/necrosis Callus present Necrosis common Minimal callus; prone 
to necrosis
Wound bed Pink and granulating, 
surrounded by callus
Pale and sloughy 
with poor 
granulation
Poor granulation
Foot temperature 
and pulses
Warm with bounding Cool with absent 
pulses
Cool with absent pulses
Other Dry skin and fissuring Delayed healing Risk of infection
Typical location Weight-bearing areas of 
the foot, such as metatarsal 
heads, the heel, and over the 
dorsum of clawed toes
Nail edges and 
between the toes 
and lateral borders 
of the foot
Margins of the foot 
and toes
Prevalence 35% 15% 50%
Risk 
category 0 
[37]
Risk category 1 Risk category 2 Risk category 3
Norma 
plantar 
sensation
Loss of plantar 
sensation
Loss of plantar sensation or poor 
circulation or foot deformity or 
onychomycosis
History of ulceration, 
neuropathic fracture, or 
amputation
Low risk Moderate risk High risk Very high risk
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• Blood sugar levels
• HbA1C
• Blood culture and sensitivity
• X-ray of the foot [38]
• MRI of the foot
• PET scan in osteomyelitis [39]
Ankle brachial index: in normal subjects, the ankle systolic pressure is higher 
than the brachial systolic pressure. The normal ABI > 1; in the presence of ischemia, 
it is <0.9. Absent or feeble pulses, with ABI < 0.9, confirm ischemia [40].
Transcutaneous oxygen tension method TcPO2 less than 20 mmHg has been 
associated with early wound healing failure [41].
• Ultrasound Doppler vascular studies
• CT angiogram
9. Diabetic foot examination
10. Treatment
Treating diabetic foot ulcer is an art and involves multiple specialties. The 
essential team members are physicians, chiropodist, orthopedics, radiologist, and 
Sensory 
exanimation
Vascular examination Deformity Ulcer examination
Vibratory perception: 
128 Hz tuning fork 
or electronic tuning 
fork
Pedal pulses: dorsalis 
pedis, posterior tibial, 
perforating peroneal
Bunions, hammertoes, 
bone spurs, 
plantarflexed 
metatarsals, pes cavus 
foot type
Area, toe, metatarsal 
forefoot, lateral, medial
Achilles reflex Erythema or cyanosis Hallux limitus, 
Achilles/
gastro equinus, 
overpronation
Ischemic or neuropathic 
or mixed
Monofilament test 10 
point touch [42]
Intermittent 
claudication score
Rocker bottom 
appearance
Small <10 cm, moderate 
11–40 cm, severe 
>40 cm
Vibration perception 
threshold (VPT)
Temperature 
comparison between 
feet
Prior amputation Cool with absent pulses
Temperature 
sensation
Dry skin and fissuring Gait evaluation Depth; probe test
Pain sensation Vascular Doppler 
ultrasonography
Foot drop, atrophy, 
necrobiosis lipoidica 
diabeticorum
Healing or nonhealing
(inflammatory 
granulating 
epithelialization)
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vascular surgeon. The focus would be ensuring targeted HbA1c, revascularization, 
wound healing with or without debridement, shading of excessive load over foot or 
limb, and limiting infection by antibiotics and assessment of complications. Focus 
on the patient’s education and nutrition is very important in reducing recurrence of 
diabetic foot ulcer.
10.1 Offloading
It means reduction, redistribution, or sharing pressures over the ulcer area. It is 
a well-known fact that offloading is one of the cornerstones of successful diabetic 
foot ulceration management and prevention. The aim is to reduce the plantar pres-
sure by redistributing it to a larger area, to avoid shear and friction, and to accom-
modate the deformities [43].
For diabetic foot ulcer, a proper cast is necessary; for example, nonremovable 
cast devices are the most clinically effective for neuropathic forefoot and mid-foot 
ulceration. The aim is to immobilize the foot and ankle within the cast, which 
significantly reduces shear force.
The total contact cast is a below-knee cast that encroaches the lower limb, encasing 
the whole foot. It is the main cast for mid- and forefoot lesions and for neuropathic 
noninfected plantar ulcers. Healing was reported in almost 100% cases of ulcers within 
5–8 weeks. For non-cast offloading devices, half shoes are designed to offload either 
the fore or rear foot. We can decide by giving examples below about casting devices:
Rear foot
For weight-bearing:
Crutches with or without a below-knee cast and a half shoe.
For non-weight-bearing:
Leg trough, pressure-relieving mattress and flexible heel cast or pillows.
Mid-foot
Total contact cast, below-knee cast, or fiberglass boot. Felt padding can be 
shaped to cover the sole of the foot with a cavity at the ulcer site.
Forefoot
Half shoe; leg- or boot-type cast is the most effective method for offloading; 
sandals with a foam-filled sink in the sole unit located over the ulcer site may also 
be useful.
Toe
Cut a hole in the part of the shoe overlying the ulcer site to remove the whole toe 
from shoe.
A recent systematic review has found nonremovable offloading devices like 
total contact cast to be more effective for ulcer healing than removable offloading 
devices [44].
11. Control of foot infection
While most DFIs are relatively superficial at presentation, microorganisms can 
spread contiguously to subcutaneous tissues, including fascia, tendons, muscle, 
joints, and bones [45, 46].
First-generation cephalosporin, clindamycin, fluoroquinolone, linezolid.
Moderate infection without systemic involvement.
Ticarcillin/clavulanate, piperacillin/tazobactam; second- or third-generation 
cephalosporin.
Diabetic Retinopathy
8
Third-generation cephalosporin, impinemen.
Ugly ulcer with systemic signs.
Ticarcillin/clavulanate, piperacillin/tazobactam; + ceftazidime, flucloxacil-
lin + cipro, carbapenem.
Ischemic limb/necrosis/gas forming.
Ticarcillin/clavulanate, piperacillin/tazobactam or carbapenem; second−/third-
generation cephalosporin + clindamycin or metronidazole.
12. Control of ischemia
Revascularization surgery: Patients with peripheral ischemia who have 
significant functional disability should undergo surgical revascularization if 
medical management fails. This may decrease the amputation risk in patients 
with ischemic DFUs.
The procedures include open (bypass grafting or endarterectomy) or endovas-
cular techniques (angioplasty with or without stent) [47].
Extracorporeal shock wave therapy acts by increasing angiogenesis and blood 
supply and cellular proliferation and thus hastening wound healing.
Low-energy lasers have also been used as an adjunctive therapy for DFUs [48].
13. Wound debridement
Ulcers heal more quickly if the surface is clean; physicians must debride impedi-
ments to healing, such as necrotic tissue and bacteria. The popular strategy is to do 
sharp debridement. So removal of necrotic tissue often extends beyond the ulcer 
bed, and some authorities have recommended to debride deeper tissues also.
Other strategy is to convert bad ulcer to fresh ulcer by excise the already an 
ulcer, underlying bony prominences. Good results have been reported with this 
approach [49].
Many other strategies of debridement include physical debridement using 
wet-to-dry dressing, enzymatic debridement using enzymes like collagenase and 
papain as ointment preparations, autolytic debridement with the use of moisture-
retaining dressings, and biological debridement with the use of larvae of common 
green bottle fly [50].
14. Wound dressings
Dressings can provide a warm, moist environment required for healing after 
debridement. Common problems associated with some of these dressings have been 
dehydration of the ulcer bed, saturation with exudate, and/or the failure to properly 
apply antibiotics and growth factors needed to promote angiogenesis and granula-
tion tissue. Non-medicated dressings include paraffin gauze, while medicated 
include Xeroform [51].
Dressing materials include saline-moistened gauze dressings (wet-to-dry), 
moisture-retaining and antiseptic dressings, silver dressings, and cadexomer.
Chemically treated honey can be used alone or in combination with sterile 
dressings [52].
In terms of ulcer healing, a meta-analysis of trials in which people with neuro-
pathic foot ulcers received good wound care reported that 24% of ulcers attained 
complete healing by 12 weeks and 31% by 20 weeks.
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In highly exuding ulcers, dressing is essential in managing the high volume of 
exudate, achieving moisture balance and preventing peri-wound soft tissue dam-
age. The frequency of wound dressing change is important in achieving these goals.
Superabsorbent dressings are designed to absorb high volumes of wound 
exudate and to hold and lock the fluid into the structure of the dressing, which may 
reduce the need for frequent dressing changes.
In a wound with low exudate levels, which contains slough, dressings should be 
selected with the aim of increasing wound moisture to aid autolysis and achieve mois-
ture balance. In the case of black, dry, and necrotic toes due to ischemia, the primary 
goal is to keep the toe dry, prevent infection, and protect adjoining or adjacent issues.
15. Nutrition and diabetic foot ulcer
As the other factors are important for proper care of diabetic foot ulcer, nutri-
tion has a pivotal role in healing, prevention of recurrence, and fair outcome. 
Unfortunately, it is a least considered part of diabetic foot ulcer management.
Imran et al. have shown that BMI was significantly associated with severity of 
ulcer; BMI of 29 was associated with grade 1 ulcer and low BMI of 23 with grade 5 
foot ulcer. Over Mini nutritional assessment scale, a score less than 23.5 was associ-
ated with advanced foot ulcers, score < 17 was associated with significant p value 
<0.03, and score in between 17 and 23.5 was associated with p value of 0.05 [53].
16. Charcot arthropathy
Charcot neuroarthropathy, or Charcot foot, is a complication of diabetes mel-
litus where there is progressive degeneration of the joints. It commonly affects the 
middle of the foot, hindfoot joints, the ankle, and forefoot joints, and it is believed 
to result from inflammation in the tissues. The prevalence of Charcot neuroar-
thropathy is approximately 13% with diabetes [54].
Charcot neuroarthropathy could result in ulceration and infection which can lead 
to amputation of the limb. Early recognition and intervention is imperative to avoid 
the rapid progression toward permanent foot deformity, ulceration, and the possibil-
ity of limb loss. Once it has started, ongoing inflammation leads to bone deformities.
The acute Charcot arthropathy results in bony reabsorption and multiple spon-
taneous fractures. Charcot joint changes can be classified into stages.
0 (prodromal): Elevated temperature, with or without foot edema and bound-
ing pulses. The X-ray of foot is less helpful.
1 Developmental, acute: An acute destructive period that is induced by minor 
trauma resulting in fragmentation of bone and joint dislocation and subluxation. 
This stage should be verified by a physician early; otherwise, misdiagnosis will lead 
to permanent deformities.
2 Subacute: The patient presents with decreased edema and healing of fractures.
3 Chronic: Healing, deformity and remodeling of bones seen on xary.
The acute phase is often misdiagnosed and can lead to permanent foot deformity 
and ulceration, thus increasing the risk of lower extremity amputation [55].
There are three types of Charcot foot classification: clinical, anatomical, and 
radiological. In clinical practice, Charcot foot can be classified into the acute and 
chronic stages [56].
The best way to deal with this stage is offloading of the foot, avoid weight-bear-
ing, prevention of aim of chronic deformities. The pain must be reduced managed 
and assessment of disease activity by physical signs, X-rays or C reactive protein.
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The surgery is indicated for correction of deformities. One researcher has been 
followed up 100 patients for a median of 3.8 years after conservative treatment for 
Charcot foot [27] and noted amputations in 2.7% and ulcer recurrence in 49%, but 
some of them have been prevented by earlier surgical intervention [57].
17. Conclusion
Diabetic foot ulcer contributes to be a major cause for morbidity in patients 
despite of multiple, advanced, and suitable interventions at different levels. This 
problem could be addressed and managed by encouraging the patient’s education, 
especially to foot care.
Patients should be motivated to care better for themselves by getting involved 
in learning programs, which highlight the risk factors and consequences of diabetic 
foot. These patients should be taught in the simple way to examine an ulcer and 
assess modified risk factors. The synthesis of national and local guidelines on 
diabetic foot care should be a priority, and the adherence to such guidelines has to 
be monitored by concerned organizations.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
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